Evaxion A/S
Business
Evaxion A/S is a clinical-stage TechBio company that applies its proprietary AI-Immunology™ platform to discover and develop vaccines for cancer and infectious diseases. It offers AI models PIONEER™, ObsERV™, AI-DeeP™, EDEN™ and RAVEN™ and advances personalized cancer vaccine candidates (EVX-01, EVX-02, EVX-03) and preclinical bacterial and viral vaccines (EVX-B1, EVX-B2, EVX-B3, EVX-V1). The company operates across AI-driven target discovery, in-house experimental screening and preclinical validation, clinical development and partnering/out-licensing. Evaxion conducts global clinical trials and collaborates with biopharmaceutical partners, CDMOs and academic partners across Europe, Australia, the U.S. and low- and middle-income country initiatives.
Summary from filing dated 2025-04-01
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-7.71M |
| Total assets | $28.41M |
| Total liabilities | $11.37M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Insider Activity
Person — A/S Evaxion
- CIK
- 0001828253
- Insider filer
- Yes
Positions
| Company | Ticker | Role | Title | Tenure |
|---|---|---|---|---|
| Evaxion A/S | EVAX | officer | CEO | 2026-03-18 |